Pharma Two B announced a poster presentation of integrated safety and efficacy data on P2B001 from its Phase 2b and Phase 3 studies in early-stage Parkinson’s disease patients. P2B001 is a fixed, low-dose extended-release combination of pramipexole, 0.6 mg and rasagiline, 0.75 mg. The data are being presented today by Henry Moore, M.D., Associate Professor of Clinical Neurology, University of Miami, Miller School of Medicine, at the Parkinson’s Study Group 33rd Annual Meeting in Nashville, TN. Pharma Two B plans to go public via a merger transaction with Hepion Pharmaceuticals (HEPA)
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HEPA:
- Hepion Pharmaceuticals’ shareholder letter urging support for Pharma Two B deal
- Hepion, Pharma Two B announce effectiveness of registration statement for merger
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
